Immix Biopharma, Inc.
IMMX
$10.97
$0.050.46%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 68.05% | 34.60% | 20.35% | 20.91% | 26.31% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 75.83% | 65.74% | 32.11% | 4.28% | 17.78% |
| Operating Income | -75.83% | -65.74% | -32.11% | -4.28% | -17.78% |
| Income Before Tax | -72.76% | -67.51% | -35.75% | -6.92% | -20.23% |
| Income Tax Expenses | -17.98% | -33.57% | -8.05% | -2.87% | 19.41% |
| Earnings from Continuing Operations | -72.60% | -67.30% | -35.67% | -6.90% | -20.22% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -100.00% | -100.00% |
| Net Income | -72.60% | -67.41% | -36.21% | -7.64% | -21.58% |
| EBIT | -75.83% | -65.74% | -32.11% | -4.28% | -17.78% |
| EBITDA | -75.34% | -64.88% | -31.22% | -3.42% | -17.24% |
| EPS Basic | -11.17% | -27.43% | -12.05% | 9.31% | 7.31% |
| Normalized Basic EPS | -11.27% | -27.62% | -12.45% | 8.87% | 6.64% |
| EPS Diluted | -11.17% | -27.43% | -12.05% | 9.31% | 7.31% |
| Normalized Diluted EPS | -11.27% | -27.62% | -12.45% | 8.87% | 6.64% |
| Average Basic Shares Outstanding | 61.19% | 34.07% | 18.55% | 17.16% | 28.18% |
| Average Diluted Shares Outstanding | 61.19% | 34.07% | 18.55% | 17.16% | 28.18% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |